Key result
Anticoagulant and/or antiaggregant therapy in adults aged 18-65 years was associated with detectable drug-drug interactions in 89.7% of patients, with 212 total interactions identified.
Why the study?
Anticoagulant and antiaggregant drugs have high mortality and represent the most common cause of malpractice.
What is the prevalence and severity of drug-drug interactions in adults aged 18-65 receiving oral anticoagulant and antiaggregant therapy?
Observational (n=122)
What is the prevalence and severity of drug-drug interactions in adults aged 18-65 receiving oral anticoagulant and antiaggregant therapy?
Drug-drug interactions are highly prevalent (89.7%) in adults aged 18-65 receiving oral anticoagulants and antiaggregants, highlighting the need for careful monitoring even in non-elderly populations.
Answers are grounded in this paper and cite their sources.
High DDI rates with antithrombotics in adults 18-65 support prescribing vigilance; leaves open outcome impact of screening.
BACKGROUND: Anticoagulant and antiaggregant drugs are drug groups with high mortality and the most common cause of malpractice. RESEARCH DESIGN AND METHODS: 18 and 65 years were scheduled for pharmacotherapy in the Family Health Center. 122 patients during their anticoagulant and/or antiaggregant treatment were evaluated in terms of drug-drug interactions. RESULTS: Drug-drug interactions were detected in 89.7% of the patients included in the study. A total of 212 drug-drug interactions were found in 122 patients. Of these, 12 (5.6%) were identified as A, 16 (7.5%) B, 146 (68.6%) C, 32 (15.2%) D and 6 (2.8%) X risk category. The number of DDI was found to be significantly higher in patients aged between 56 and 65 years. The most drug interactions are significantly higher in the C and D categories, respectively. The most predicted clinical outcomes of DDI's were increased in the therapeutic effect and adverse/toxic reactions. CONCLUSIONS: Contrary to expectations, it is seen that although polypharmacy is relatively less in patients aged 18-65 years compared to patients over 65 years of age, it is very important to detect drug interactions in this age group in terms of safety, efficacy and treatment benefit in terms of drug-drug interaction.
No takes yet. Share an insight, caveat, or question.
Ketenci et al. (2023) conducted an observational in Receiving anticoagulant and/or antiaggregant therapy (n=122). Anticoagulant and/or antiaggregant therapy was evaluated on Drug-drug interactions. Anticoagulant and/or antiaggregant therapy in adults aged 18-65 years was associated with detectable drug-drug interactions in 89.7% of patients, with 212 total interactions identified.
Synapse has enriched 10 related papers. Consider them for comparative context: